Inovio Biomedical (AMEX: INO) is developing a robust pre-clinical and early clinical stage pipeline of innovative DNA-based vaccines and therapeutics that target cancer, influenza, and other infectious diseases (e.g. HIV) based on its SynCon DNA vaccine construct and electroporation DNA delivery technology platforms.
MedTech Sentinal Special Edition Advamed 2009 Presenting Companies by Tasmia Khan The line up of medical device companies presenting at Advamed 2009 has been set. Forty-eight companies will […]
Acadia and its partner Biovail made news last month with a failed late-stage trial of pimavanserin, their experimental drug candidate to treat psychosis related to Parkinson’s disease.
CVT’s system, currently under development, is the first self-conforming and self-anchoring technology for transcatheter mitral valve implantation (TVMI).
The race for an anti-obesity drug intensified Wednesday with the latest mid-stage trial data from Orexigen Therapeutics.
On 9/22/09, BioSante and Cell Genesys (NASDAQ: CEGE) announced that they have determined the final exchange ratio will be 0.1828 in connection with the previously announced merger between the companies.
After a long delay, Centocor Ortho Biotech’s psoriasis drug Stelara has been approved by the U.S. Food and Drug Administration.
Follow OneMedPlace on Twitter to discover the latest happenings in the life sciences industry.
Earlier this month, Audiopoint added its voice to the list of companies developing EHR products.
Scientists are calling Plexxikon’s experimental skin cancer drug a “breakthrough” after it successfully shrank tumors in clinical trial patients.
Copyright © 2025 | WordPress Theme by MH Themes